<DOC>
	<DOCNO>NCT02668302</DOCNO>
	<brief_summary>Randomized , control , double-blinded clinical trial 40 patient randomize 1:1 ratio either treatment ( bilateral in-office placement Propel follow ESS ) control ( post ESS standard care ) group follow 6 month</brief_summary>
	<brief_title>The PIO II Study In-office Placement Steroid-eluting Sinus Implant</brief_title>
	<detailed_description>This prospective , randomize , double-blinded , controlled trial aim assess efficacy drug-eluting sinus implant placement follow ethmoidectomy addition post-op standard care ( i.e . debridement , irrigation , topical steroid ) compare standard care alone ( control ) . A total 40 patient enrol one site randomize 1:1 ratio either treatment control group . Patients return follow-up examination 2 week 1 , 3 6 month placement . Follow-up examination consist patient-reported outcome endoscopic grade clinical investigator independent blind reviewer base video-endoscopy review .</detailed_description>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>Confirmed diagnosis chronic rhinosinusitis , define AAOHNS 2015 guideline , include presence bilateral ethmoid disease . ESS include bilateral ethmoidectomy middle meatal antrostomy within 7 day prior schedule implant placement . Concurrent septoplasty surgical treatment paranasal sinuses also permit . Known history intolerance corticosteroid oral steroiddependent condition . Known history immune deficiency , insulindependent diabetes , cataract , glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Steroid-eluting implant</keyword>
	<keyword>Mometasone furoate</keyword>
</DOC>